Shares in ARS Pharmaceuticals were in freefall in pre-market trading this morning as it emerged that the FDA had declined to approve its application for its lead product, aiming to become the first ...
Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback